Formulary guidance and transparency from P&T to point of care

Trends That Matter for HIV

Posted by Matt Breese on Feb 15, 2018

Find me on:


In our weekly Trends that Matter series, we provide infographics, articles and recent news from health care influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is HIV. 

According to our recent payer coverage analysis for HIV, combined with news from key health care influencers, market access is shifting in this drug landscape. 

Here are some recent trends:

  • Patient Information Protection: New York Attorney General Eric Schneiderman on Jan.23 announced a settlement with Aetna Inc., following claims that the insurer revealed the HIV status of 2,460-some New York members via a mailing list July in which the envelopes’ oversize transparent address window revealed text confirming the members’ HIV status. Organizations are pushing to develop and approve methods to monitor patient adherence. Aetna will pay a $1.15 million civil penalty.  
  • Generic Implications for HIV: “Some HIV drugs are going generic,” which is “certainly a positive thing,” as specialty drugs don’t go generic very often, according to Reg Blackburn at The Braff Group. While biosimilars are not the same as generics, it is worth paying close attention to their evolvution, payment structure, adoption and impact on pricing. Once patients are stabilized on a specialty drug, it is not a simple thing to switch them to another therapy. 

To learn more about this topic, download MMIT's Reality Check by clicking on the button below: 

View Reality Check 

Topics: Specialty, Industry Trends